Skip to main content
LFMD
NASDAQ Life Sciences

LifeMD Lands Exclusive Deal for XYOSTED Testosterone Program, Targeting Millions of Men

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.88
Mkt Cap
$229.722M
52W Low
$2.56
52W High
$15.84
52W Position info
91% above low
Off High info
69% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

LFMD sits 91% above its 52-week low of $2.56.

Summary

LifeMD announced an exclusive co-marketing collaboration with Halozyme's Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED (testosterone enanthate) injection. This program, launching in July 2026 across 37 states, makes LifeMD the exclusive telehealth partner and preferred dispensing pharmacy for the FDA-approved once-weekly testosterone auto-injector. The initiative targets millions of men with hypogonadism, offering a transparent $249/month price for medication and care, which could significantly boost LifeMD's subscriber base and revenue. This strategic partnership comes after LifeMD reported a wider net loss and a debt covenant breach in Q1 2026, making new revenue streams particularly important. The program's launch in July will be a key event to watch.

At the time of this announcement, LFMD was trading at $4.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.7M. The 52-week trading range was $2.56 to $15.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LFMD - Latest Insights

LFMD
Nov 12, 2026, 4:58 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $1.82 info
Change: +$0.210 (+13%) info
Market Cap: $86.759M info
LFMD
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.49
Real-time Price: $1.82 info
Change: +$0.330 (+22%) info
Market Cap: $86.759M info
LFMD
Nov 12, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.54
Real-time Price: $1.82 info
Change: +$0.2799 (+18%) info
Market Cap: $86.759M info
LFMD
Nov 09, 2026, 9:39 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $1.98
Real-time Price: $1.82 info
Change: -$0.160 (-8%) info
Market Cap: $86.759M info
LFMD
Sep 15, 2026, 10:18 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.30
Real-time Price: $1.82 info
Change: -$1.47 (-45%) info
Market Cap: $86.759M info